StemCell Therapy

What Every Parent Should Know About Raising a T1D Kid  Health Central

More:
What Every Parent Should Know About Raising a T1D Kid - Health Central

New findings on pancreatic anatomy may affect diabetes research and treatment  Medical Xpress

See the article here:
New findings on pancreatic anatomy may affect diabetes research and treatment - Medical Xpress

The role of yogurt in diabetes and obesity prevention  News-Medical.Net

View original post here:
The role of yogurt in diabetes and obesity prevention - News-Medical.Net

How exercising outdoors can prevent depression and diabetes  inews

Read more here:
How exercising outdoors can prevent depression and diabetes - inews

Heart of the Valley: Valley woman discusses how she improved her health following diabetes diagnosis  KRGV

Read this article:
Heart of the Valley: Valley woman discusses how she improved her health following diabetes diagnosis - KRGV

The Right Amount of Sleep Could Help Prevent This Extremely Common Disease  Inverse

See the original post:
The Right Amount of Sleep Could Help Prevent This Extremely Common Disease - Inverse

'Bread and Butter': Societies Issue T2D Management Guidance  Medscape

Continued here:
'Bread and Butter': Societies Issue T2D Management Guidance - Medscape

Glycemic index of diets: importance beyond diabetes control  The Hindu

Read more from the original source:
Glycemic index of diets: importance beyond diabetes control - The Hindu

She was fired after not endorsing Splenda-filled salads to people with diabetes. Why?  The Guardian

Originally posted here:
She was fired after not endorsing Splenda-filled salads to people with diabetes. Why? - The Guardian

MIAMI, April 15, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for a Featured Research Oral Presentation to present the Company’s CLEAR MIND Phase 2a study results. CLEAR-MIND is a Phase 2a randomized clinical trial evaluating Lomecel-BTM in mild Alzheimer’s Disease. In addition to the clinical study results, the Company has been accepted for a poster presentation at the 2024 Alzheimer’s Association International Conference (AAIC), to be held July 28 – August 1, 2024 in Philadelphia, PA, USA and online.

Here is the original post:
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research...

OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen (rintatolimod) as a potential treatment for Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID.

Follow this link:
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs

Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138 Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138

See the original post here:
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

An important step in Kane becoming a market leader in the growing high-value wound care and dermatological markets An important step in Kane becoming a market leader in the growing high-value wound care and dermatological markets

Originally posted here:
Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products

AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (“Cassava Sciences” or the "Company") today announced that Monday, May 6, 2024 is the last and final day to exercise the warrants that were previously distributed to its shareholders on January 3, 2024 (the “Warrants”). Holders who exercise their Warrants will receive 1.5 shares of Cassava Sciences’ common stock per Warrant, for an effective price of approximately $22.00 per share.

Read the rest here:
Redemption Date Announced for Warrants

LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 27th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) to be held in Baltimore May 7-11, 2024.

More:
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American...

Publication Annual Report – Annual Shareholders' Meeting

The rest is here:
Publication Annual Report – Annual Shareholders' Meeting

Basel, April 15, 2024 – Novartis today presented results from a pre-specified interim analysis of the Phase III APPLAUSE-IgAN study of Fabhalta® (iptacopan), an investigational Factor B inhibitor of the alternative complement pathway, in patients with IgA nephropathy (IgAN)1. In the analysis, patients treated with Fabhalta achieved a 38.3% (p<0.0001) proteinuria reduction (as measured by 24-hour urine protein to creatinine ratio [UPCR]) at 9 months when compared to placebo on top of supportive care1.

Continue reading here:
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for...

SYDNEY, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce that enrolment has opened for its expansion study in bile tract cancer (cholangiocarcinoma) patients, having completed the fifth, high dose cohort in the intratumoural (IT) arm of the monotherapy dose escalation study evaluating its cancer-killing virus CF33-hNIS (VAXINIA).

More:
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the April 15, 2024 French legal announcements bulletin n°46 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on May 22, 2024, at 10:00am (CET), at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.

See the article here:
GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

MONTREAL, April 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has mailed its 2024 management proxy circular to shareholders in connection with its virtual annual meeting of shareholders to be held on May 9, 2024, at 10:00 a.m. ET.

Read the original post:
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders